ipilimumab
Trade name: yervoy
mAbapprovedOrphan Drug FDA
Approved
Mar 25, 2011
Ipilimumab, sold under the brand name Yervoy, is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system. — Wikipedia
Clinical trial activity
749 trials · 348 clinical orgs · 1 marketing orgs
Phase 1
319
Phase 2
518
Phase 3
81
Phase 4
6
Earliest trial started Aug 1, 2001 (NCT00028431)
Timeline
2000s
- Jan 1, 2001
Earliest Phase 1 Sponsor(trial)
- Jan 1, 2002
Earliest Phase 2 Sponsor(trial)
- Jan 1, 2004
Bristol-Myers Squibb — Earliest Phase 3 Sponsor(trial)
- Jun 3, 2004
Orphan Drug Designation
2010s
- Mar 25, 2011
Bristol-Myers Squibb — Earliest FDA Approval
- Mar 25, 2011
Bristol-Myers Squibb — Marketing Organization
- Mar 25, 2011
Bristol-Myers Squibb — NDA Organization
Indications
Approved for
Studied for
- Adenocarcinoma · Phase 2
- Adenocarcinoma, Clear Cell · Phase 2
- Adenocarcinoma, Mucinous · Phase 2
- Adenocarcinoma of Lung · Phase 3
- Adrenal Gland Neoplasms · Phase 2
- Adrenocortical Carcinoma · Phase 2
- Anaplastic Lymphoma Kinase · Phase 1/Phase 2
- Anemia · Phase 1
- Antibodies · Phase 2
- Anus Neoplasms · Phase 3
- Appendicitis · Phase 2
- Astrocytoma · Phase 2
- Basal Cell Carcinoma · Phase 2
- Basal Cell Nevus Syndrome · Phase 2
- Bile Duct Neoplasms · Phase 2
- Biliary Tract Neoplasms · Phase 2
- Biomarkers · Phase 1/Phase 2
- Brain Neoplasms · Phase 3
- Breast Neoplasms · Phase 2
- Burkitt Lymphoma · Phase 1/Phase 2
- Carcinoid Tumor · Phase 2
- Carcinoma · Phase 2
- Carcinoma, Acinar Cell · Phase 2
- Carcinoma, Adenoid Cystic · Phase 2
- Carcinoma, Endometrioid · Phase 2
- Carcinoma, Giant Cell · Phase 2
- Carcinoma, Hepatocellular · Phase 3
- Carcinoma, Merkel Cell · Phase 3
- Carcinoma, Mucoepidermoid · Phase 2
- Carcinoma, Neuroendocrine · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 3
- Carcinoma, Renal Cell · Phase 4
- Carcinoma, Squamous Cell · Phase 2
- Carcinoma, Transitional Cell · Phase 3
- Carcinosarcoma · Phase 2
- Castration · Phase 2
- Cholangiocarcinoma · Phase 3
- Chondrosarcoma · Phase 2
- Chordoma · Phase 2
- Choriocarcinoma · Phase 2
- Chromatin · Phase 2
- Colonic Neoplasms · Phase 3
- Colorectal Neoplasms · Phase 3
- Colorectal Neoplasms, Hereditary Nonpolyposis · Phase 1
- COVID-19 · Phase 2
- Cystadenocarcinoma, Mucinous · Phase 2
- Cystadenocarcinoma, Serous · Phase 2
- Desmoplastic Small Round Cell Tumor · Phase 2
- DNA Mismatch Repair · Phase 1/Phase 2
- DNA Repair-Deficiency Disorders · Phase 1
- Drug-Related Side Effects and Adverse Reactions · Phase 1
- Drugs, Investigational · Phase 2
- Endometrial Neoplasms · Phase 2
- Esophageal Neoplasms · Phase 3
- Esophageal Squamous Cell Carcinoma · Phase 1/Phase 2
- Fallopian Tube Neoplasms · Phase 2
- Fibrosarcoma · Phase 2
- Gallbladder Neoplasms · Phase 2
- Gastrointestinal Neoplasms · Phase 2
- Gastrointestinal Stromal Tumors · Phase 2
- GATA2 Deficiency · Phase 1
- General Surgery · Phase 2
- Genital Neoplasms, Male · Phase 2
- Germ Cells · Phase 2
- Gestational Trophoblastic Disease · Phase 2
- Glioblastoma · Phase 3
- Glioma · Phase 2
- Gliosarcoma · Phase 2/Phase 3
- Hamartoma · Phase 2
- Head and Neck Neoplasms · Phase 3
- Healthy Volunteers · Phase 1
- Hemangiosarcoma · Phase 2
- Hematopoietic Stem Cell Transplantation · Phase 1
- Hepatitis B · Phase 2
- Hepatitis C · Phase 2
- Hepatoblastoma · Phase 2
- HIV · Phase 2
- HIV Infections · Phase 1
- Hodgkin Disease · Phase 2
- Immunotherapy · Phase 1/Phase 2
- Infusions, Intravenous · Phase 4
- Intestinal Neoplasms · Phase 2
- Intraocular Lymphoma · Phase 1/Phase 2
- Kidney Diseases · Phase 3
- Kidney Neoplasms · Phase 4
- Larynx · Phase 1/Phase 2
- Leiomyosarcoma · Phase 2
- Leukemia · Phase 2
- Leukemia, Biphenotypic, Acute · Phase 2
- Leukemia, Hairy Cell · Phase 1/Phase 2
- Leukemia, Large Granular Lymphocytic · Phase 1/Phase 2
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1/Phase 2
- Leukemia-Lymphoma, Adult T-Cell · Phase 1/Phase 2
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Phase 1
- Leukemia, Myeloid, Acute · Phase 2
- Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative · Phase 1
- Leukemia, Myeloid, Chronic-Phase · Phase 1
- Leukemia, Myelomonocytic, Chronic · Phase 2
- Lip · Phase 1/Phase 2
- Lip Diseases · Early Phase 1
- Liposarcoma · Phase 2
- Liver Neoplasms · Phase 3
- Lung Neoplasms · Phase 3
- Lymphoma · Phase 1/Phase 2
- Lymphoma, B-Cell · Phase 1
- Lymphoma, B-Cell, Marginal Zone · Phase 1/Phase 2
- Lymphoma, Follicular · Phase 1/Phase 2
- Lymphoma, Large B-Cell, Diffuse · Phase 1/Phase 2
- Lymphoma, Large-Cell, Anaplastic · Phase 1/Phase 2
- Lymphoma, Large-Cell, Immunoblastic · Phase 2
- Lymphoma, Mantle-Cell · Phase 1/Phase 2
- Lymphoma, Non-Hodgkin · Phase 2
- Lymphoma, Primary Cutaneous Anaplastic Large Cell · Phase 1
- Lymphoma, T-Cell · Phase 1/Phase 2
- Lymphoma, T-Cell, Peripheral · Phase 1/Phase 2
- Lymphomatoid Granulomatosis · Phase 1/Phase 2
- Meningeal Carcinomatosis · Phase 2
- Meningioma · Phase 1/Phase 2
- Mesothelioma · Phase 3
- Mesothelioma, Malignant · Phase 2
- Microsatellite Instability · Phase 2
- Mouth Neoplasms · Phase 2
- Multiple Myeloma · Phase 2
- Mutation · Phase 1
- Mycosis Fungoides · Phase 1
- Myelodysplastic Syndromes · Phase 2
- Myeloproliferative Disorders · Phase 1
- Nasopharyngeal Carcinoma · Phase 2
- Neoplasm Metastasis · Phase 3
- Neoplasms by Site · Phase 2
- Neoplasms, Multiple Primary · Phase 3
- Nerve Sheath Neoplasms · Phase 1
- Neuroblastoma · Phase 2
- Neuroendocrine Tumors · Phase 2
- Neurofibrosarcoma · Phase 2
- Oncogenes · Phase 1
- Oropharyngeal Neoplasms · Phase 2
- Osteosarcoma · Phase 2
- Ovarian Diseases · Phase 1
- Ovarian Neoplasms · Phase 2
- Paget Disease, Extramammary · Phase 2
- Pancreatic Neoplasms · Phase 2
- Papillomavirus Infections · Phase 2
- Paraganglioma · Phase 2
- Penile Neoplasms · Phase 2
- Peritoneal Neoplasms · Phase 2
- Perivascular Epithelioid Cell Neoplasms · Phase 2
- Pharyngeal Neoplasms · Phase 1/Phase 2
- Pheochromocytoma · Phase 2
- Pituitary Diseases · Phase 2
- Pituitary Neoplasms · Phase 2
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Phase 1
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 1
- Primary Myelofibrosis · Phase 1
- Prostatic Diseases · Phase 2
- Prostatic Neoplasms · Phase 3
- Prostatic Neoplasms, Castration-Resistant · Phase 2
- Proto-Oncogene Proteins c-kit · Phase 1
- Pseudomyxoma Peritonei · Phase 2
- Rectal Neoplasms · Phase 2
- Rhabdoid Tumor · Phase 2
- Rhabdomyosarcoma · Phase 2
- Salivary Gland Neoplasms · Phase 2
- Sarcoma · Phase 3
- Sarcoma, Ewing · Phase 2
- Sarcoma, Kaposi · Phase 2
- Sarcoma, Synovial · Phase 2
- Seminoma · Phase 2
- Sezary Syndrome · Phase 1/Phase 2
- Skin Neoplasms · Phase 2
- Small Cell Lung Carcinoma · Phase 3
- Squamous Cell Carcinoma of Head and Neck · Phase 3
- Stomach Neoplasms · Phase 3
- Testicular Neoplasms · Phase 2
- Thyroid Neoplasms · Phase 2
- Tracheal Neoplasms · Phase 2
- Triple Negative Breast Neoplasms · Phase 2
- Ureteral Neoplasms · Phase 2
- Urethral Neoplasms · Phase 2
- Urinary Bladder Neoplasms · Phase 3
- Urogenital Neoplasms · Phase 2
- Uterine Cervical Neoplasms · Phase 3
- Vaginal Neoplasms · Phase 2
- Vulvar Neoplasms · Phase 2
- Waldenstrom Macroglobulinemia · Phase 1/Phase 2
- Wilms Tumor · Phase 2
- Xeroderma Pigmentosum · Phase 1
Mechanism of action
- Cytotoxic T-lymphocyte protein 4INHIBITOR
CTLA4 inhibitor
Approval history
- approvedMar 25, 2011
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
- Multi-specific
- No
Oral
No
Parenteral
Yes
Topical
No
First in class
Sources
- WikipediaIpilimumab ↗
- NCATS6T8C155666 ↗
- ChEMBLCHEMBL1789844 ↗
Also known as
- ipilimumab
- ipilimumab
- ipilimumab
- ipilimumab
- ipilimumab
- ipilimumab
- ipilimumab
- ipilimumab
- ipilimumab
- ipilimumab
- mdx010
- mdx010
- mdx 010
- mdx-010
- mdx-010
- mdx-010
- mdx-010
- mdx-010
- mdx-101
- mdx-101
- mdx-ctla4
- mdx-ctla-4
- mdx-ctla-4
- mdx-ctla-4
- mdx-ctla-4
- moab-ctla-4
- yervoy
- yervoy
- yervoy
- yervoy
- yervoy
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07293351 | Phase 1/Phase 2 (Phase 2) | Mar 26, 2026 | Biontech, Bristol-Myers Squibb |
| NCT07291076 | Phase 1/Phase 2 (Phase 2) | Feb 9, 2026 | Biontech, Bristol-Myers Squibb |
| NCT06999980 | Phase 2 | Dec 31, 2025 | Bristol-Myers Squibb, Melanoma Institute Australia |
| NCT07128680 | Phase 1 | Dec 5, 2025 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT07075120 | Phase 1 | Dec 1, 2025 | University of Hawaii |
| NCT07227012 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2025 | Pfizer |
| NCT07233668 | N/A | Dec 1, 2025 | Seoul National University |
| NCT07230613 | Phase 2 | Dec 1, 2025 | UNICANCER |
| NCT07188896 | Phase 2 | Nov 30, 2025 | Hoosier Cancer Research Network, Regeneron, Vanderbilt University |
| NCT06968988 | Phase 1 | Nov 30, 2025 | Exelixis, Washington University in St. Louis |
| NCT07166406 | Phase 3 | Nov 27, 2025 | NRG Oncology |
| NCT07176650 | Phase 1 | Oct 31, 2025 | Shanghai Henlius Biotech |
| NCT07155317 | Phase 2 | Oct 29, 2025 | Emory University, National Cancer Institute (NCI) |
| NCT06946797 | Phase 2 | Sep 19, 2025 | Bristol-Myers Squibb |
| NCT06941857 | Phase 2 | Sep 4, 2025 | Johns Hopkins University, Lustgarten Foundation, NextCure, Inc. |
| NCT07160647 | Phase 2 | Aug 20, 2025 | Zhejiang University |
| NCT07000149 | Phase 3 | Jul 28, 2025 | Arcus Biosciences, Inc., AstraZeneca |
| NCT07134842 | Phase 1 | Jul 10, 2025 | University of London |
| NCT06889493 | Phase 1 | May 19, 2025 | University of Miami |
| NCT06823479 | Phase 2 | May 14, 2025 | Erasmus University Rotterdam, Free University of Amsterdam, Maastricht University, Netherlands Cancer Institute, Utrecht University |
Showing 20 of 749 trials
Page 1 / 38
Organizations
Research & Development (348)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 305 | 123 | 5 | 2002 |
| National Cancer Institute (NCI) | Government | 126 | 66 | 3 | 2001 |
| University of Texas at Houston | Academic/Hospital | 48 | 44 | 4 | 2010 |
| Harvard University | Academic/Hospital | 33 | 25 | 2 | 2002 |
| Johns Hopkins University | Academic/Hospital | 22 | 15 | 4 | 2009 |
| Cornell University | Academic/Hospital | 18 | 11 | 3 | 2005 |
| Netherlands Cancer Institute | Academic/Hospital | 18 | 17 | 3 | 2014 |
| University of South Florida | Academic/Hospital | 17 | 15 | 4 | 2010 |
| Ono Pharmaceuticals | For profit | 15 | 1 | 3 | 2009 |
| National Institutes of Health (NIH) | Government | 13 | 3 | 2 | 2002 |
| University of Copenhagen | Academic/Hospital | 13 | 11 | 3 | 2014 |
| University of Pittsburgh | Academic/Hospital | 13 | 9 | 3 | 2009 |
| Medarex | For profit | 12 | 0 | 3 | 2003 |
| ECOG-ACRIN Cancer Research Group | Academic/Hospital | 11 | 1 | 3 | 2010 |
| Merck | For profit | 11 | 5 | 3 | 2012 |
| Exelixis | For profit | 10 | 2 | 3 | 2019 |
| Institut Gustave Roussy | Academic/Hospital | 10 | 8 | 3 | 2011 |
| University of California, San Francisco | Academic/Hospital | 10 | 5 | 2 | 2003 |
| Duke University | Academic/Hospital | 8 | 7 | 2 | 2013 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 8 | 7 | 2 | 2018 |
348 organizations
Page 1 / 18
Marketing (2)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Bristol-Myers Squibb | For profit | MKTG | Mar 25, 2011 |
| Bristol-Myers Squibb | For profit | NDA | Mar 25, 2011 |